Medicare Part B: TECELRA (afamitresgene autoleucel)
Customize your policy alerts
Sign up for all MVP Health Care policy alerts
Know when MVP Health Care releases new policies or updates existing guidance.
Monitor payer policy activity
Medicare Part B prior authorization and coverage for TECELRA, an autologous T-cell immunotherapy, for eligible MVP Health Care Medicare Advantage members with unresectable or metastatic synovial sarcoma.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.